What is it about?
For decades, scientists have been looking for ways to circumvent resistance of cancer cells to therapy. In this study, we utilized CRISPR metabolic screen to identify genes of resistance to inhibitors of DNA repair kinase ATM. We discovered that a gene called KEAP1 is particularly required for invasive breast and lung cancer cells to survive upon ATM kinase inhibition.
Photo by Nalini Maheshwari on Unsplash
Why is it important?
Our study provides strong evidence supporting the stratification of patients with KEAP1-mutants tumors as likely responders to ATM inhibitors.
Read the Original
This page is a summary of: CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors, Proceedings of the National Academy of Sciences, February 2023, Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.2212072120.
You can read the full text:
The following have contributed to this page